公开(公告)号：US20160339052A1

公开(公告)日：2016-11-24

申请号：US15076513

申请日：2016-03-21

Applicant: CoDa Therapeutics, Inc.

Inventor： Anthony PHILLIPS ,  David EISENBUD ,  Scott BANNAN ,  Grove MATSUOKA ,  David POOL ,  Tracey SUNDERLAND ,  Bradford DUFT

IPC: A61K31/7088 ,  A61K9/00 ,  A61B5/107 ,  A61K9/06 ,  A61K9/70 ,  A61B5/00 ,  C12N15/113 ,  A61K47/10

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

Abstract translation: 本发明涉及通过施用抗连接蛋白剂，特别是抗连接蛋白43反义多核苷酸治疗慢性伤口的改进的方法，用途和试剂盒。 本发明的方法，用途和试剂盒基于惊人的和意想不到的发现，即在预处理阶段期间，不增加或减少大小超过预定量的慢性伤口比成功治疗更适合于比 在预处理阶段，其大小在目标范围之外变化的伤口。

公开(公告)号：US20160331805A1

公开(公告)日：2016-11-17

申请号：US15012732

申请日：2016-02-01

Applicant: CoDa Therapeutics, Inc.

Inventor： Colin Richard GREEN ,  David Lawrence BECKER

IPC: A61K38/17 ,  C12N15/115

CPC classification number: A61K38/177 ,  A61K31/70 ,  A61K38/08 ,  A61K38/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/705 ,  C12N15/115 ,  C12N2310/11 ,  C12N2310/16 ,  C12N2320/30 ,  Y02P20/582 ,  A61K2300/00

Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use for treatment of cardiovascular, vascular, neurological, for wounds and for other indications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication or prevention of hemichannel opening is desirable.

Abstract translation: 提供了调节连接蛋白活性的方法和组合物，包括例如用于治疗心血管，血管，神经系统，伤口和其他适应症的治疗。 这些化合物和方法可以在治疗上使用，例如降低相关疾病和病症的不良反应的严重性，其中需要直接细胞 - 细胞通信或预防半通道开放的局部破坏。

公开(公告)号：US09290554B2

公开(公告)日：2016-03-22

申请号：US14214922

申请日：2014-03-15

Applicant: CoDa Therapeutics, Inc.

Inventor： Anthony Phillips ,  David Eisenbud ,  Scott Bannan ,  David Pool ,  Grove Matsuoka ,  Tracey Sunderland ,  Bradford Duft

IPC: C12N15/113 ,  C07K14/47 ,  A61B5/107 ,  A61B5/11 ,  A61B5/00 ,  A61K31/7088 ,  A61K47/00 ,  A61K9/00 ,  A61K48/00

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

公开(公告)号：US09193754B2

公开(公告)日：2015-11-24

申请号：US13681383

申请日：2012-11-19

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence Becker ,  Colin Richard Green

IPC: C07H21/04 ,  C07H21/02 ,  A61K31/70 ,  C12N15/11 ,  C12N15/113 ,  A61K31/711 ,  C12Q1/68

CPC classification number: C07H21/04 ,  A61K31/711 ,  A61K38/00 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2320/32

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

公开(公告)号：US09156896B2

公开(公告)日：2015-10-13

申请号：US13844762

申请日：2013-03-15

Applicant: CoDa Therapeutics, Inc.

Inventor： Anthony Phillips ,  David Eisenbud ,  Scott Bannan ,  David Pool ,  Grove Matsuoka ,  Tracey Sunderland ,  Bradford Duft

IPC: C12N15/113 ,  C07K14/47 ,  A61B5/107 ,  A61B5/11 ,  A61B5/00 ,  A61K31/7088 ,  A61K47/00 ,  A61K9/00 ,  A61K48/00

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

Abstract translation: 本发明涉及通过施用抗连接蛋白剂，特别是抗连接蛋白43反义多核苷酸治疗慢性伤口的改进的方法，用途和试剂盒。 本发明的方法，用途和试剂盒基于惊人的和意想不到的发现，即在预处理阶段期间，不增加或减少大小超过预定量的慢性伤口比成功治疗更适合于比 在预处理阶段，其大小在目标范围之外变化的伤口。

公开(公告)号：US20150232842A1

公开(公告)日：2015-08-20

申请号：US14642582

申请日：2015-03-09

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence BECKER ,  Colin Richard GREEN ,  Bradford James DUFT

IPC: C12N15/113 ,  A61K45/06 ,  A61K31/7088

CPC classification number: C12N15/113 ,  A61K31/7088 ,  A61K45/06 ,  A61L15/44 ,  A61L26/0066 ,  A61L2300/258 ,  A61L2300/432 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/315 ,  Y02A50/423

Abstract: Treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations and articles.

Abstract translation: 纤维化和纤维化疾病，病症和病症以及相关方法，组合物，制剂和制品的治疗。

公开(公告)号：US20140371297A1

公开(公告)日：2014-12-18

申请号：US14467978

申请日：2014-08-25

Applicant: CoDa Therapeutics, Inc.

Inventor： Wilda LAUX ,  Colin Richard GREEN

IPC: C12N15/113

CPC classification number: C12N15/113 ,  A61K31/7105 ,  A61K31/711 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/315 ,  C12N2320/31 ,  Y02P20/582

Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.

Abstract translation: 提供了用于调节连接蛋白活性的方法和组合物，包括例如用于手术后外伤，创伤或组织工程应用。 这些化合物和方法可以在治疗上使用，例如，降低相关疾病和病症的不良反应的严重性，其中期望直接细胞 - 细胞通讯的局部中断。

公开(公告)号：US10201590B2

公开(公告)日：2019-02-12

申请号：US15012732

申请日：2016-02-01

Applicant: CoDa Therapeutics, Inc.

Inventor： Colin Richard Green ,  David Lawrence Becker

IPC: A61K38/08 ,  A61K38/10 ,  A61K38/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/705 ,  A61K31/70 ,  C12N15/115

Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use for treatment of cardiovascular, vascular, neurological, for wounds and for other indications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication or prevention of hemichannel opening is desirable.

公开(公告)号：US20170296571A1

公开(公告)日：2017-10-19

申请号：US15284389

申请日：2016-10-03

Applicant: CODA THERAPEUTICS, INC.

Inventor： Colin R. GREEN ,  Bradford J. DUFT ,  David L. BECKER

IPC: A61K31/711 ,  C12N15/113 ,  A61K45/06 ,  A61K35/36 ,  A61K35/33 ,  A61K38/18 ,  A61K38/17

CPC classification number: A61K31/711 ,  A61K35/33 ,  A61K35/36 ,  A61K38/1754 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/1858 ,  A61K45/06 ,  C12N15/1138 ,  C12N2310/11 ,  A61K2300/00

Abstract: Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair.

公开(公告)号：US09738892B2

公开(公告)日：2017-08-22

申请号：US14642582

申请日：2015-03-09

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence Becker ,  Colin Richard Green ,  Bradford James Duft

IPC: A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/113 ,  A61K31/7088 ,  A61K45/06

CPC classification number: C12N15/113 ,  A61K31/7088 ,  A61K45/06 ,  A61L15/44 ,  A61L26/0066 ,  A61L2300/258 ,  A61L2300/432 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/315 ,  Y02A50/423

Abstract: Treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations and articles.